This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
type i | 733 |
type diabetes | 580 |
study design | 532 |
case studies | 482 |
background case | 481 |
design method | 387 |
results finding | 375 |
please specify | 254 |
abstract type | 254 |
type ii | 227 |
i interferon | 199 |
blood bank | 188 |
red blood | 183 |
diabetes mellitus | 177 |
outcome measures | 169 |
main outcome | 169 |
cell types | 158 |
i ifn | 154 |
epithelial cells | 151 |
research abstract | 151 |
abstract background | 151 |
results findings | 145 |
whole blood | 139 |
design methods | 138 |
see chapter | 133 |
blood donors | 131 |
viral infections | 126 |
immune response | 123 |
fcov type | 120 |
virus infection | 120 |
influenza virus | 118 |
blood center | 118 |
innate immune | 112 |
blood cells | 111 |
acute respiratory | 109 |
gene expression | 107 |
blood group | 106 |
viral infection | 105 |
npy npf | 104 |
descriptive abstract | 103 |
cell death | 103 |
blood products | 96 |
red cell | 96 |
blood cell | 96 |
amino acid | 94 |
dendritic cells | 94 |
porcine circovirus | 93 |
medication reconciliation | 93 |
mg dl | 91 |
liver disease | 90 |
respiratory syndrome | 88 |
histologic study | 88 |
immune responses | 86 |
interstitial pneumonia | 85 |
risk factors | 85 |
i signaling | 84 |
lymph nodes | 83 |
insulin resistance | 82 |
united states | 82 |
side effects | 81 |
least one | 80 |
bone marrow | 80 |
blood components | 80 |
associated conditions | 79 |
type receptors | 78 |
possible associated | 78 |
fatty liver | 78 |
human beings | 78 |
diabetic patients | 76 |
rbc units | 76 |
performed using | 75 |
lung cancer | 74 |
severe acute | 74 |
i interferons | 72 |
respiratory tract | 72 |
specimen preparation | 72 |
transfusion medicine | 72 |
see also | 71 |
listeria monocytogenes | 71 |
electron microscopy | 70 |
health care | 69 |
pasteurella multocida | 68 |
expected findings | 68 |
spinal cord | 68 |
blood product | 67 |
clinical pharmacist | 67 |
type iii | 67 |
stem cell | 66 |
medication adherence | 66 |
sjs ten | 65 |
transfusion service | 65 |
toxic epidermal | 64 |
related terms | 64 |
infected cells | 64 |
cell lines | 63 |
significantly higher | 63 |
university hospital | 63 |
epidermal necrolysis | 62 |
respiratory distress | 62 |
immune system | 61 |
bacterial infections | 61 |
clinical pharmacy | 61 |
mean age | 60 |
blood transfusion | 60 |
pulmonary edema | 59 |
i collagen | 59 |
years old | 58 |
cell type | 58 |
external examination | 58 |
primary care | 57 |
medical center | 57 |
submit samples | 57 |
flow cytometry | 57 |
patient care | 57 |
may also | 56 |
alveolar macrophages | 56 |
viral replication | 56 |
endothelial cells | 56 |
clinical signs | 56 |
turbulence divergence | 56 |
adverse effects | 56 |
cell surface | 56 |
public health | 55 |
clinically significant | 55 |
cord uid | 55 |
doc id | 55 |
blood donor | 55 |
secondary bacterial | 55 |
type peptides | 55 |
retrospective study | 55 |
intensive care | 54 |
transfusion reactions | 54 |
per patient | 54 |
growth factor | 54 |
patient safety | 54 |
antibody screen | 54 |
rhce ce | 54 |
nervous system | 53 |
feline infectious | 53 |
infectious peritonitis | 53 |
statistically significant | 52 |
ng ml | 52 |
transcription factors | 51 |
pulmonary fibrosis | 51 |
clinical trials | 50 |
nasal cavity | 50 |
important role | 50 |
smooth muscle | 50 |
quality control | 50 |
blood donation | 50 |
transcription factor | 49 |
hong kong | 49 |
drug interactions | 49 |
hand column | 49 |
platelet count | 49 |
adverse drug | 49 |
positive samples | 48 |
high levels | 48 |
sting pathway | 48 |
potential discovery | 48 |
infectious diseases | 48 |
may occur | 48 |
case report | 47 |
coli colony | 47 |
escherichia coli | 47 |
red cells | 47 |
stem cells | 47 |
adverse events | 46 |
center background | 46 |
medical record | 46 |
clinical practice | 46 |
significant differences | 46 |
drug reactions | 45 |
peripheral blood | 45 |
massive transfusion | 45 |
significant difference | 44 |
procedures depend | 44 |
submit sample | 44 |
ii pneumonocytes | 44 |
present study | 44 |
immune cells | 44 |
host cell | 43 |
abo rh | 43 |
interferon signaling | 43 |
i production | 43 |
emergency department | 42 |
blood donations | 42 |
blood centers | 42 |
results suggest | 42 |
disease progression | 42 |
adaptive immune | 42 |
grossly identified | 41 |
ifn production | 41 |
amino acids | 41 |
innate immunity | 41 |
defense mechanisms | 41 |
johnson syndrome | 41 |
herpes simplex | 41 |
circovirus type | 41 |
may cause | 41 |
alveolar walls | 41 |
total number | 41 |
i responses | 40 |
patients treated | 40 |
blood pressure | 40 |
patients received | 40 |
cell responses | 40 |
risk factor | 40 |
clinical pharmacists | 40 |
pharmaceutical care | 40 |
identified abnormalities | 40 |
nucleic acid | 40 |
sickle cell | 39 |
blood type | 39 |
francisella tularensis | 39 |
high risk | 39 |
people aged | 39 |
pathogen reduction | 39 |
sustentacular cells | 39 |
nk cells | 39 |
two different | 39 |
respiratory disease | 39 |
one patient | 38 |
lung injury | 38 |
rbc transfusion | 38 |
transfected cells | 38 |
blood glucose | 38 |
within hours | 37 |
weight loss | 37 |
granted medrxiv | 37 |
virus replication | 37 |
connective tissue | 37 |
room temperature | 37 |
author funder | 37 |
septal defect | 36 |
blood services | 36 |
apheresis platelets | 36 |
red cross | 36 |
viral loads | 36 |
patients receiving | 36 |
signaling pathways | 36 |
viral rna | 36 |
clinical trial | 36 |
blood supply | 36 |
related problems | 36 |
clinical outcomes | 35 |
syndrome coronavirus | 35 |
systematic review | 35 |
blood loss | 35 |
version posted | 35 |
type neuropeptides | 35 |
study period | 35 |
heart disease | 35 |
session types | 35 |
hpv types | 35 |
blood samples | 35 |
copyright holder | 35 |
pulmonary disease | 35 |
adverse reactions | 34 |
results indicate | 34 |
medical records | 34 |
oxidative stress | 34 |
inflammatory cytokines | 34 |
staphylococcus aureus | 34 |
inflammatory response | 34 |
community pharmacy | 34 |
aged years | 34 |
drug hypersensitivity | 34 |
epithelial cell | 34 |
cell carcinoma | 34 |
electronic medical | 33 |
renal failure | 33 |
cd cells | 33 |
feline coronavirus | 33 |
respiratory viral | 33 |
high prevalence | 33 |
viral load | 33 |
blood vessels | 33 |
protein kinase | 33 |
immunodeficiency virus | 33 |
beta cells | 33 |
procedures described | 33 |
wild type | 33 |
distress syndrome | 32 |
severe cases | 32 |
care unit | 32 |
lupus erythematosus | 32 |
among patients | 32 |
necrosis factor | 32 |
sequence analysis | 32 |
blood volume | 32 |
year old | 32 |
prospective study | 32 |
i ifns | 32 |
body weight | 32 |
plasmacytoid dendritic | 32 |
pulmonary alveolar | 32 |
patient blood | 31 |
significantly different | 31 |
alpha beta | 31 |
respiratory system | 31 |
heart failure | 31 |
also found | 31 |
bacterial infection | 31 |
mannheimia haemolytica | 31 |
nonalcoholic fatty | 31 |
domestic animals | 31 |
widely used | 31 |
previously described | 31 |
central nervous | 31 |
pneumonic mannheimiosis | 31 |
world health | 31 |
increased risk | 30 |
made available | 30 |
systemic lupus | 30 |
alcoholic fatty | 30 |
endoplasmic reticulum | 30 |
dm patients | 30 |
closely related | 30 |
cell cycle | 30 |
statistical analysis | 30 |
results showed | 30 |
medrxiv preprint | 30 |
tumor necrosis | 30 |
transfusion reaction | 30 |
cell disease | 30 |
toxicologic study | 29 |
ifn signaling | 29 |
transfusion vol | 29 |
tumor cells | 29 |
early stages | 29 |
determine whether | 29 |
colony types | 29 |
community pharmacies | 29 |
one year | 29 |
natural killer | 29 |
may lead | 29 |
hemolytic anemia | 29 |
education program | 29 |
days post | 29 |
small cell | 29 |
novel coronavirus | 29 |
upper respiratory | 29 |
month period | 29 |
colony type | 29 |
idiopathic pulmonary | 29 |
human immunodeficiency | 28 |
cell lung | 28 |
autoimmune diseases | 28 |
monoclonal antibodies | 28 |
per day | 28 |
internal medicine | 28 |
pharmaceutical interventions | 28 |
lung disease | 28 |
significant increase | 28 |
two groups | 28 |
enzootic pneumonia | 28 |
genomic dna | 28 |
cytosolic dna | 28 |
rheumatoid arthritis | 28 |
infectious disease | 28 |
positive results | 27 |
dendritic cell | 27 |
plasma exchange | 27 |
two major | 27 |
inclusion criteria | 27 |
mouse model | 27 |
hemolytic transfusion | 27 |
air embolism | 27 |
cell line | 27 |
blood management | 27 |
host defense | 27 |
health professionals | 27 |
disease severity | 27 |
tobacco smoke | 27 |
per year | 27 |
bacterial pneumonia | 27 |
patients using | 27 |
median age | 27 |
binding sites | 27 |
diabetes education | 27 |
transfusion services | 27 |
type signalling | 26 |
inflammatory cells | 26 |
high titer | 26 |
false positive | 26 |
chronic viral | 26 |
acid sequence | 26 |
medication review | 26 |
blood alcohol | 26 |
human papillomavirus | 26 |
blood component | 26 |
pulmonary lesions | 26 |
oral cavity | 26 |
significantly increased | 26 |
lcmv infection | 26 |
gross lesions | 26 |
fibrinous bronchopneumonia | 26 |
cell proliferation | 26 |
pulmonary hypertension | 26 |
cell identity | 26 |
observational study | 26 |
south texas | 26 |
blood banks | 26 |
two cases | 26 |
breast cancer | 26 |
cov plpro | 26 |
health organization | 26 |
antiviral activity | 26 |
mast cells | 26 |
significantly lower | 26 |
see table | 26 |
open reading | 26 |
nk cell | 26 |
monocytogenes infection | 26 |
antibody identification | 25 |
feline coronaviruses | 25 |
healthcare professionals | 25 |
nitric oxide | 25 |
animal models | 25 |
lesser extent | 25 |
suppurative bronchopneumonia | 25 |
tyrosine kinase | 25 |
american red | 25 |
previous studies | 25 |
simplex virus | 25 |
i pneumonocytes | 25 |
coronary artery | 25 |
care units | 25 |
year period | 25 |
myocardial infarction | 25 |
nasal mucosa | 25 |
international license | 25 |
regulatory factor | 25 |
older adults | 25 |
human adult | 25 |
additional file | 25 |
wide range | 25 |
tested positive | 25 |
coronavirus infection | 25 |
type diabetic | 25 |
outer membrane | 25 |
large amounts | 25 |
adaptive immunity | 25 |
bact alert | 25 |
nucleotide sequence | 25 |
signaling pathway | 25 |
type fimbriae | 24 |
carbon monoxide | 24 |
drug related | 24 |
plasma cells | 24 |
full text | 24 |
mycobacterium tuberculosis | 24 |
cell culture | 24 |
basement membrane | 24 |
analysis revealed | 24 |
literature review | 24 |
like peptide | 24 |
molecular weight | 24 |
flow cytometric | 24 |
mononuclear cells | 24 |
ifn response | 24 |
drug therapy | 24 |
control group | 24 |
nursing home | 24 |
peer review | 24 |
hiv positive | 24 |
inflammatory process | 24 |
type specific | 24 |
low levels | 23 |
prrp snpf | 23 |
class i | 23 |
adipose tissue | 23 |
adult pancreas | 23 |
different types | 23 |
cigarettes day | 23 |
mg kg | 23 |
spike protein | 23 |
sars coronavirus | 23 |
virus type | 23 |
airway obstruction | 23 |
phylogenetic analysis | 23 |
included patients | 23 |
cell cultures | 23 |
skeletal muscle | 23 |
long term | 23 |
platelet concentrates | 23 |
inducing ligand | 23 |
reading frame | 23 |
systemic symptoms | 23 |
also observed | 23 |
monoclonal antibody | 23 |
analyzed using | 23 |
molecular mechanisms | 23 |
nonalcoholic steatohepatitis | 23 |
cytokine production | 23 |
systemic involvement | 23 |
polymerase chain | 23 |
chain reaction | 23 |
skin lesions | 23 |
ventricular septal | 23 |
related apoptosis | 23 |
diabetic ketoacidosis | 23 |
echinoderm prrp | 23 |
host cells | 22 |
proinflammatory cytokines | 22 |
iu ml | 22 |
critical role | 22 |
community pharmacists | 22 |
large cell | 22 |
units transfused | 22 |
study group | 22 |
patient samples | 22 |
cd cd | 22 |
common type | 22 |
logistic regression | 22 |
clinical manifestations | 22 |
transfusion practice | 22 |
giant cells | 22 |
microscopic examination | 22 |
france please | 22 |
cohort study | 22 |
dna binding | 22 |
bacterial contamination | 22 |
platelet counts | 22 |
mrna levels | 22 |
dependent manner | 22 |
pregnant women | 22 |
inflammatory responses | 22 |
zika virus | 22 |
time period | 22 |
even though | 22 |
cord blood | 22 |
interferon response | 22 |
cancer cells | 21 |
study shows | 21 |
frozen plasma | 21 |
drug reaction | 21 |
blood safety | 21 |
donor center | 21 |
follow procedures | 21 |
thrombotic thrombocytopenic | 21 |
glucose tolerance | 21 |
one week | 21 |
urinary tract | 21 |
recent studies | 21 |
bowel disease | 21 |
snpf prrpr | 21 |
information system | 21 |
tract infections | 21 |
regional blood | 21 |
will also | 21 |
lung cancers | 21 |
north america | 21 |
mortality rates | 21 |
average age | 21 |
listeria infection | 21 |
multidisciplinary team | 21 |
significantly reduced | 21 |
sting signaling | 21 |
coronavirus disease | 21 |
svev mice | 21 |
clinical course | 21 |
cardiovascular disease | 21 |
interferon receptor | 21 |
metabolic syndrome | 21 |
snpf prrp | 21 |
kidney disease | 21 |
vena cava | 21 |
fungal infections | 21 |
posted august | 21 |
toxoplasma gondii | 21 |
several studies | 21 |
results show | 21 |
per month | 21 |
cell lymphoma | 21 |
inventory management | 21 |
incidence rates | 21 |
npf prrp | 21 |
alveolar proteinosis | 21 |
olfactory epithelium | 21 |
adhesion molecules | 20 |
medication reviews | 20 |
plasma membrane | 20 |
hospital stay | 20 |
mayo clinic | 20 |
may result | 20 |
cell activation | 20 |
essential role | 20 |
cutaneous adrs | 20 |
binding protein | 20 |
muscle cells | 20 |
chronic inflammation | 20 |
immune cell | 20 |
protostome snpf | 20 |
two types | 20 |
tertiary care | 20 |
interstitial pneumonias | 20 |
goblet cells | 20 |
second biennium | 20 |
cell membrane | 20 |
mouse hepatitis | 20 |
clinical symptoms | 20 |
hypersensitivity reactions | 20 |
conducting system | 20 |
time pcr | 20 |
west nile | 20 |
ca i | 20 |
gene regulatory | 20 |
antiviral response | 20 |
human disease | 20 |
regression analysis | 20 |
pulmonary artery | 20 |
response rate | 20 |
nucleic acids | 20 |
granulomatous pneumonia | 20 |
scd patients | 20 |
platelet products | 20 |
transfusion protocol | 20 |
commonly seen | 20 |
tissue culture | 19 |
chronic bronchitis | 19 |
inflammatory bowel | 19 |
peritonitis virus | 19 |
persistent viral | 19 |
may play | 19 |
common cause | 19 |
old male | 19 |
respiratory syncytial | 19 |
situ hybridization | 19 |
fipv type | 19 |
previously reported | 19 |
cell differentiation | 19 |
trauma patients | 19 |
rhd gene | 19 |
aortic arch | 19 |
thrombocytopenic purpura | 19 |
mortality rate | 19 |
blood collection | 19 |
medication discrepancies | 19 |
hospital pharmacy | 19 |
gastrointestinal tract | 19 |
antigen expression | 19 |
apheresis platelet | 19 |
chronic infection | 19 |
sequence data | 19 |
like receptors | 19 |
cd deficiency | 19 |
reference laboratory | 19 |
first step | 19 |
clinical disease | 19 |
differential diagnosis | 19 |
therapeutic plasma | 19 |
plasma units | 19 |
deferral rates | 19 |
evaluated using | 19 |
tissue injury | 19 |
iav infection | 19 |
age groups | 19 |
also cause | 19 |
clinical features | 19 |
white blood | 19 |
reverse transcriptase | 19 |
types i | 19 |
binding site | 19 |
alveolar capillaries | 19 |
canadian blood | 19 |
treated cells | 19 |
protein gene | 19 |
platelet inventory | 19 |
coli strains | 19 |
serum albumin | 19 |
alveolar epithelial | 19 |
linear regression | 19 |
aspiration pneumonia | 19 |
cell carcinomas | 19 |
recent study | 19 |
middle east | 19 |
monoclonal anti | 18 |
patients included | 18 |
sequence identity | 18 |
cystic fibrosis | 18 |
rare donor | 18 |
least two | 18 |
fatty acids | 18 |
conducted using | 18 |
pulmonary arteries | 18 |
clinical impact | 18 |
analysis showed | 18 |
fold higher | 18 |
future studies | 18 |
two main | 18 |
samples tested | 18 |
molecular basis | 18 |
steady state | 18 |
pharmacy service | 18 |
chest imaging | 18 |
general population | 18 |
national blood | 18 |
hospital transfusion | 18 |
impaired glucose | 18 |
liver fat | 18 |
receptor complex | 18 |
hematopoietic stem | 18 |
like protease | 18 |
copies ml | 18 |
old female | 18 |
nile virus | 18 |
membrane protein | 18 |
clinically relevant | 18 |
data collected | 18 |
pharmacist intervention | 18 |
rbc transfusions | 18 |
mechanical ventilation | 18 |
bronchointerstitial pneumonia | 18 |
expression levels | 18 |
syncytial virus | 18 |
early stage | 18 |
cell count | 18 |
cell function | 18 |
alveolar epithelium | 18 |
platelet units | 18 |
elderly patients | 18 |
blood flow | 18 |
hcv infection | 18 |
mice infected | 18 |
hepatitis virus | 18 |
interferon regulatory | 18 |
microbiologic study | 18 |
lymph node | 18 |
small number | 18 |
pancreatic cell | 18 |
host immune | 18 |
species transmission | 17 |
medical history | 17 |
factor receptor | 17 |
bordetella bronchiseptica | 17 |
serum samples | 17 |
high level | 17 |
study aimed | 17 |
binding proteins | 17 |
data collection | 17 |
three major | 17 |
infected mice | 17 |
large numbers | 17 |
converting enzyme | 17 |
pediatric patients | 17 |
hospitalized patients | 17 |
last years | 17 |
molecular mass | 17 |
rhd beadchip | 17 |
like peptides | 17 |
critical type | 17 |
drug eruptions | 17 |
real time | 17 |
increased expression | 17 |
commercially available | 17 |
virus control | 17 |
mammary gland | 17 |
first biennium | 17 |
ethics committee | 17 |
cyclic gmp | 17 |
standard deviation | 17 |
olfactory bulb | 17 |
interferon responses | 17 |
treated rbcs | 17 |
shelf life | 17 |
patients undergoing | 17 |
large number | 17 |
hospital background | 17 |
two patients | 17 |
prosthetic repair | 17 |
rejuvenation solution | 17 |
cytokine storm | 17 |
streptococcus pneumoniae | 17 |
blood ordering | 17 |
adult patients | 17 |
thoracic cavity | 17 |
respiratory infections | 17 |
retrospective review | 17 |
nursing staff | 17 |
pleural surface | 17 |
echinoderm receptors | 17 |
squamous cell | 17 |
age group | 17 |
mhv infection | 17 |
highly conserved | 17 |
controlled trial | 17 |
acute interstitial | 17 |
another study | 17 |
significantly decreased | 17 |
alcoholic steatohepatitis | 17 |
chronic disease | 17 |
female donors | 17 |
pathogen inactivation | 17 |
antitrypsin deficiency | 17 |
alveolar interstitium | 17 |
respiratory infection | 17 |
clinical response | 17 |
platelet transfusion | 17 |
phagocytic cells | 17 |
interlobular septa | 17 |
chronic inflammatory | 17 |
renal function | 17 |
eye drops | 17 |
molecular testing | 17 |
humoral immunity | 17 |
protein expression | 17 |
histologic sections | 17 |
protein synthesis | 17 |
amp synthase | 17 |
signal transduction | 17 |
iron deficiency | 17 |
cell rna | 17 |
mean number | 17 |
two distinct | 17 |
vitro quality | 17 |
positive cells | 17 |
elevated levels | 17 |
patient received | 17 |
binding domain | 16 |
record weight | 16 |
ace expression | 16 |
tube testing | 16 |
alveolar wall | 16 |
mass index | 16 |
pharmacy practice | 16 |
cell populations | 16 |
genes involved | 16 |
cell apoptosis | 16 |
health system | 16 |
allowed us | 16 |
serologic testing | 16 |
pilot study | 16 |
analysed using | 16 |
trna lys | 16 |
leucocyte depleted | 16 |
stranded dna | 16 |
erythema multiforme | 16 |
deficient mice | 16 |
described previously | 16 |
acute lung | 16 |
preliminary results | 16 |
fat content | 16 |
hepatocellular carcinoma | 16 |
part ii | 16 |
target genes | 16 |
fold increase | 16 |
multiple myeloma | 16 |
repeat testing | 16 |
newly diagnosed | 16 |
recent years | 16 |
exanthematous pustulosis | 16 |
higher levels | 16 |
cell receptor | 16 |
high throughput | 16 |
brain stem | 16 |
previous study | 16 |
extracellular matrix | 16 |
data analysis | 16 |
national health | 16 |
nasal discharge | 16 |
related genes | 16 |
also known | 16 |
pleural effusion | 16 |
clinical characteristics | 16 |
body mass | 16 |
neuropeptide signalling | 16 |
acquired immunodeficiency | 16 |
clin pharm | 16 |
incidence trends | 16 |
septic shock | 16 |
env gene | 16 |
fresh frozen | 16 |
serum levels | 16 |
commonly used | 16 |
marrow transplantation | 16 |
hemolytic uremic | 16 |
blood service | 16 |
general practitioners | 16 |
vaccinia virus | 16 |
bronchial epithelial | 16 |
sequence similarity | 16 |
less common | 16 |
donor samples | 16 |
surface area | 16 |
rhodococcus equi | 16 |
growth factors | 16 |
antibody screening | 16 |
cell hyperplasia | 16 |
paranasal sinuses | 16 |
loading dose | 16 |
dna sensing | 16 |
new automated | 16 |
basal lamina | 16 |
prepare roentgenograms | 16 |
buffy coat | 16 |
amniotic fluid | 16 |
within days | 16 |
reactive oxygen | 16 |
immune activation | 16 |
lymphoid cells | 16 |
liver fibrosis | 16 |
high dose | 16 |
test results | 16 |
interferon alpha | 16 |
renal disease | 16 |
alveolar damage | 16 |
oral chemotherapy | 16 |
broad spectrum | 16 |
lung diseases | 16 |
alveolar spaces | 16 |
wild boar | 16 |
mouse mammary | 16 |
life cycle | 16 |
manual tube | 16 |
high frequency | 16 |
imaging studies | 16 |
east respiratory | 16 |
enhanc pre | 16 |
ml min | 16 |
severe cutaneous | 16 |
siv infection | 16 |
volume reduction | 16 |
blood system | 16 |
transplant recipients | 15 |
right ventricle | 15 |
coronary arteries | 15 |
dtt treatment | 15 |
viral genome | 15 |
ferritin levels | 15 |
cell adhesion | 15 |
three different | 15 |
atrophic rhinitis | 15 |
type drug | 15 |
core sars | 15 |
mrna expression | 15 |
uremic syndrome | 15 |
healthy south | 15 |
average number | 15 |
increased susceptibility | 15 |
group antigen | 15 |
voluntary blood | 15 |
cause severe | 15 |
free radicals | 15 |
inclusion bodies | 15 |
specific cell | 15 |
rbcs stored | 15 |
infective endocarditis | 15 |
dna damage | 15 |
ace protein | 15 |
animal model | 15 |
hyaline membranes | 15 |
adverse event | 15 |
antiglobulin test | 15 |
also reported | 15 |
virulence factors | 15 |
reagent red | 15 |
critically ill | 15 |
glycaemic control | 15 |
ciliated cells | 15 |
tumor suppressor | 15 |
liver transplant | 15 |
type unspecified | 15 |
negative blood | 15 |
bacterial culture | 15 |
turnaround time | 15 |
management system | 15 |
mycobacterium bovis | 15 |
light microscopy | 15 |
express ace | 15 |
autopsy procedures | 15 |
predictive value | 15 |
terumo bct | 15 |
hepatic steatosis | 15 |
trail signaling | 15 |
rhd diiia | 15 |
stimulated genes | 15 |
patient population | 15 |
epidermal growth | 15 |
infected patients | 15 |
additive solution | 15 |
european countries | 15 |
salmonella enterica | 15 |
sting activation | 15 |
amotosalen uva | 15 |
group viii | 15 |
beta cell | 15 |
receptor binding | 15 |
social media | 15 |
fatty acid | 15 |
sars literature | 15 |
also occur | 15 |
blood systems | 15 |
virus adsorption | 15 |
cost savings | 15 |
different cell | 15 |
hemolytic disease | 15 |
cell entry | 15 |
type interferon | 15 |
insulin secretion | 15 |
sanger sequencing | 15 |
stored rbcs | 15 |
multiparty session | 15 |
also present | 15 |
clinical significance | 15 |
patient counselling | 15 |
retrospective analysis | 15 |
alveolar space | 15 |
improve patient | 15 |
chronic hepatitis | 15 |
patients admitted | 15 |
arachidonic acid | 15 |
assessed using | 15 |
statistical significance | 15 |
capsular types | 15 |
transmission electron | 15 |
clinical relevance | 15 |
diffuse alveolar | 15 |
general practitioner | 15 |
ifnar signaling | 15 |
plasma samples | 15 |
bystander cells | 15 |
ill patients | 15 |
genes encoding | 15 |
dna sensor | 15 |
serum sickness | 15 |
cancer patients | 15 |
rbc unit | 15 |
group antigens | 15 |
donor screening | 15 |
african americans | 15 |
marker genes | 15 |
per unit | 15 |
negative results | 15 |
university school | 15 |
small intestine | 14 |
results obtained | 14 |
quality improvement | 14 |
multiple sclerosis | 14 |
emergency release | 14 |
also may | 14 |
hcv rna | 14 |
significant association | 14 |
much higher | 14 |
dose adjustment | 14 |
key role | 14 |
healthcare system | 14 |
medication history | 14 |
chronic cases | 14 |
medical care | 14 |
induced hypersensitivity | 14 |
hospital pharmacists | 14 |
tube method | 14 |
white matter | 14 |
dna synthesis | 14 |
body fluids | 14 |
blot analysis | 14 |
infection type | 14 |
high glucose | 14 |
naturally occurring | 14 |
source data | 14 |
sialic acid | 14 |
pathogen reduced | 14 |
risk assessment | 14 |
bovine serum | 14 |
cutaneous adverse | 14 |
schwann cells | 14 |
sudden death | 14 |
iron metabolism | 14 |
diabetes increased | 14 |
microscopic lesions | 14 |
hemoglobin levels | 14 |
highly pathogenic | 14 |
cells expressing | 14 |
positive feedback | 14 |
transgenic mice | 14 |
three patients | 14 |
significant impact | 14 |
molecular pathology | 14 |
serious adverse | 14 |
diabetes care | 14 |
significantly associated | 14 |
th cells | 14 |
respiratory failure | 14 |
neg rbc | 14 |
medical treatment | 14 |
informed consent | 14 |
drug administration | 14 |
immune status | 14 |
transfused patients | 14 |
guttural pouch | 14 |
inflammatory diseases | 14 |
target cells | 14 |
post infection | 14 |
clinical presentation | 14 |
donor population | 14 |
cellular identity | 14 |
pharmaceutical analysis | 14 |
associated protein | 14 |
lymphoid tissue | 14 |
comparator assay | 14 |
negative rbcs | 14 |
contour lines | 14 |
medication knowledge | 14 |
pancreatic beta | 14 |
endothelial cell | 14 |
significant antibodies | 14 |
protein sequence | 14 |
frozen sections | 14 |
molecular analysis | 14 |
commonly found | 14 |
solid phase | 14 |
posted october | 14 |
pharmaceutical validation | 14 |
related complications | 14 |
study showed | 14 |
signalling systems | 14 |
rbc products | 14 |
pneumocystis carinii | 14 |
coronavirus infections | 14 |
group i | 14 |
breast milk | 14 |
poorly understood | 14 |
viral defenses | 14 |
type pneumocytes | 14 |
crucial role | 14 |
antibody screens | 14 |
interferon induction | 14 |
chronic obstructive | 14 |
nasal passages | 14 |
different clinical | 14 |
lung tissue | 14 |
male donors | 14 |
distilled water | 14 |
randomized controlled | 14 |
potentially inappropriate | 14 |
immunodeficiency syndrome | 14 |
binary session | 14 |
single cell | 14 |
direct antiglobulin | 14 |
haemophilus influenzae | 14 |
clinical information | 14 |
equine influenza | 14 |
streptococcus equi | 14 |
significant reduction | 14 |
regional lymph | 14 |
viral dna | 14 |
blood screening | 14 |
using two | 14 |
advanced glycation | 14 |
authors declare | 14 |
beta interferon | 14 |
er stress | 13 |
recently reported | 13 |
also occurs | 13 |
data suggest | 13 |
scanning electron | 13 |
environmental factors | 13 |
cell exhaustion | 13 |
results demonstrate | 13 |
human lung | 13 |
single unit | 13 |
malignant mesothelioma | 13 |
organ failure | 13 |
donated blood | 13 |
adhesion molecule | 13 |
basic anomaly | 13 |
emergency blood | 13 |
high affinity | 13 |
mediated immunity | 13 |
standard tube | 13 |
hbv dna | 13 |
genotyping results | 13 |
high degree | 13 |
gel electrophoresis | 13 |
herbal products | 13 |
canine distemper | 13 |
programmed cell | 13 |
foam cells | 13 |
highly expressed | 13 |
cigarette smoke | 13 |
square test | 13 |
zikv rna | 13 |
cell histiocytosis | 13 |
lung tissues | 13 |
age years | 13 |
higher risk | 13 |
three times | 13 |
glucose levels | 13 |
ifn induction | 13 |
hospital admission | 13 |
hepatic insulin | 13 |
fda approved | 13 |
low ferritin | 13 |
enteric pathogens | 13 |
among different | 13 |
clinical outcome | 13 |
blood count | 13 |
acute pancreatitis | 13 |
false negative | 13 |
potential discoveries | 13 |
also detected | 13 |
virus survival | 13 |
pharmaceutical services | 13 |
hla antibodies | 13 |
observed among | 13 |
serologic studies | 13 |
infectious agents | 13 |
acute generalized | 13 |
angiotensin ii | 13 |
phylogenetic tree | 13 |
kidney failure | 13 |
given atypical | 13 |
days later | 13 |
generalized exanthematous | 13 |
stranded rna | 13 |
endogenous betaretroviruses | 13 |
will require | 13 |
diabetic mice | 13 |
likely due | 13 |
like receptor | 13 |
studies suggest | 13 |
mesenchymal stem | 13 |
stat activation | 13 |
one unit | 13 |
methenamine silver | 13 |
medication lists | 13 |
first time | 13 |
iii ifn | 13 |
trauma center | 13 |
goblet cell | 13 |
increased levels | 13 |
type neuropeptide | 13 |
patients hospitalized | 13 |
transfusion transmitted | 13 |
potential role | 13 |
studies showed | 13 |
host disease | 13 |
cd cell | 13 |
fusion proteins | 13 |
pathogenic bacteria | 13 |
interferon genes | 13 |
five patients | 13 |
gastric contents | 13 |
alcohol concentration | 13 |
oxygen species | 13 |
progenitor cells | 13 |
drug eruption | 13 |
pluripotent stem | 13 |
patients showed | 13 |
rhd genotyping | 13 |
see disease | 13 |
medication errors | 13 |
patients without | 13 |
may contribute | 13 |
nar sequences | 13 |
irradiated blood | 13 |
xcr dcs | 13 |
pulmonary surfactant | 13 |
mass spectrometry | 13 |
rna viruses | 13 |
stopp criteria | 13 |
ascending aorta | 13 |
virus infections | 13 |
reactive samples | 13 |
cell transplantation | 13 |
sensory neurons | 13 |
hcv treatment | 13 |
storage lesion | 13 |
positive impact | 13 |
capsular type | 13 |
proper use | 13 |
physical activity | 13 |
i subtypes | 13 |
acceptance rate | 13 |
chronic diseases | 13 |
sectional study | 13 |
type receptor | 13 |
high incidence | 13 |
fecv type | 13 |
transfusion testing | 13 |
persistent lcmv | 12 |
replacement fluid | 12 |
major role | 12 |
short neuropeptide | 12 |
expressing cells | 12 |
may affect | 12 |
collected using | 12 |
chester disease | 12 |
lung pathology | 12 |
myeloid cells | 12 |
million people | 12 |
kg day | 12 |
following influenza | 12 |
controlled trials | 12 |
laboratory tests | 12 |
animals exposed | 12 |
predicted phenotype | 12 |
also tested | 12 |
obstructive pulmonary | 12 |
also performed | 12 |
etiologic agent | 12 |
human pancreatic | 12 |
two days | 12 |
ulcerative colitis | 12 |
chest pain | 12 |
within weeks | 12 |
among participants | 12 |
gene encoding | 12 |
four patients | 12 |
total rna | 12 |
dissection techniques | 12 |
literature search | 12 |
new zealand | 12 |
specific sera | 12 |
chi square | 12 |
anal swabs | 12 |
heparan sulfate | 12 |
islet cell | 12 |
respiratory viruses | 12 |
polio vaccine | 12 |
rhd negative | 12 |
better understand | 12 |
retrospective observational | 12 |
academic medical | 12 |
diabetic complications | 12 |
patients compared | 12 |
plasma proteins | 12 |
group system | 12 |
clinical data | 12 |
distemper virus | 12 |
parenteral nutrition | 12 |
alloimmunized patients | 12 |
cov infection | 12 |
broad range | 12 |
one study | 12 |
mycoplasma hyopneumoniae | 12 |
hospital blood | 12 |
transfusion recipients | 12 |
significant decrease | 12 |
inflammasome activation | 12 |
ml kg | 12 |
neuronal cell | 12 |
interferon production | 12 |
homologous recombination | 12 |
ductal artery | 12 |
thawed plasma | 12 |
screening test | 12 |
antigen negative | 12 |
human coronavirus | 12 |
langerhans cell | 12 |
allergic alveolitis | 12 |
mammalian cells | 12 |
reference range | 12 |
time point | 12 |
tranexamic acid | 12 |
viral particles | 12 |
chronic lung | 12 |
many cases | 12 |
responder patients | 12 |
diabetic individuals | 12 |
also used | 12 |
month follow | 12 |
hypersensitivity syndrome | 12 |
better understanding | 12 |
donate blood | 12 |
signal peptide | 12 |
higher incidence | 12 |
stat pathway | 12 |
smoke exposure | 12 |
reverse transcription | 12 |
sglt inhibitors | 12 |
relatively low | 12 |
hla alleles | 12 |
cell migration | 12 |
diabetes type | 12 |
type precursors | 12 |
may represent | 12 |
one lung | 12 |
rat brain | 12 |
nat yield | 12 |
acid sequences | 12 |
poults given | 12 |
diabetes management | 12 |
hpv prevalence | 12 |
confirmed positive | 12 |
immature platelet | 12 |
acute kidney | 12 |
specific antibodies | 12 |
type mice | 12 |
large volume | 12 |
ppis prescriptions | 12 |
based transfusion | 12 |
patient harm | 12 |
blood supplier | 12 |
lamina propria | 12 |
ms ms | 12 |
glycation end | 12 |
based blood | 12 |
also involved | 12 |
parainfluenza virus | 12 |
genome sequence | 12 |
signalling system | 12 |
culture results | 12 |
hiv infection | 12 |
pcr assay | 12 |
cells express | 12 |
rhd weak | 12 |
randomized clinical | 12 |
continuous variables | 12 |
guttural pouches | 12 |
second messenger | 12 |
presenting cells | 12 |
tested using | 12 |
lymphatic vessels | 12 |
human pancreas | 12 |
highly variable | 12 |
median time | 12 |
lung epithelial | 12 |
clinical studies | 12 |
past years | 12 |
exclusion criteria | 12 |
older people | 12 |
poliovirus type | 12 |
oral anticoagulants | 12 |
way valve | 12 |
sample size | 12 |
pancreatic cancer | 12 |
beneficial effects | 12 |
hla class | 12 |
surface antigen | 12 |
hours post | 12 |
air barrier | 12 |
antiviral responses | 11 |
taken together | 11 |
hod otii | 11 |
fcov types | 11 |
mononuclear cell | 11 |
ph levels | 11 |
defense mechanism | 11 |
skeletal muscles | 11 |
donor plasma | 11 |
side effect | 11 |
neutralizing antibodies | 11 |
care professionals | 11 |
record extent | 11 |
high rates | 11 |
land application | 11 |
cell units | 11 |
hpv dna | 11 |
lung parenchyma | 11 |
phone calls | 11 |
common ancestor | 11 |
average blood | 11 |
among men | 11 |
gene sequencing | 11 |
dpg levels | 11 |
treatment duration | 11 |
buffy coats | 11 |
pulmonary parenchyma | 11 |
retrospective cohort | 11 |
focus group | 11 |
technician related | 11 |
sewage effluent | 11 |
phase ii | 11 |
life expectancy | 11 |
coronavirus papain | 11 |
hpv positive | 11 |
abo typing | 11 |
automated bp | 11 |
urinary bladder | 11 |
induced apoptosis | 11 |
onset type | 11 |
poor prognosis | 11 |
influenza infection | 11 |
direct contact | 11 |
ifn receptor | 11 |
cells using | 11 |
cat sera | 11 |
pulmonary valve | 11 |
wound healing | 11 |
apheresis donors | 11 |
experimental studies | 11 |
underlying conditions | 11 |
hematology analyzer | 11 |
general dissection | 11 |
final concentration | 11 |
compatible blood | 11 |
pulmonary hemorrhage | 11 |
medical devices | 11 |
care service | 11 |
many years | 11 |
factors associated | 11 |
chart review | 11 |
cells ml | 11 |
blood groups | 11 |
mucosal surfaces | 11 |
viral pneumonia | 11 |
mice lacking | 11 |
diabetes incidence | 11 |
multiparty channel | 11 |
pharmacist notes | 11 |
chronic granulomatous | 11 |
silver stain | 11 |
part iv | 11 |
low adherence | 11 |
ii ifn | 11 |
human plasma | 11 |
high mortality | 11 |
first described | 11 |
alveolar septa | 11 |
similar results | 11 |
primary health | 11 |
plt count | 11 |
reportable disease | 11 |
case reports | 11 |
phylogenetic analyses | 11 |
naturally infected | 11 |
median number | 11 |
ab plasma | 11 |
cd tregs | 11 |
mediated immune | 11 |
nucleotide sequences | 11 |
remains unclear | 11 |
rh typing | 11 |
genetic variants | 11 |
paraffin sections | 11 |
much lower | 11 |
pulmonary neuroendocrine | 11 |
blood transfusions | 11 |
central role | 11 |
fowl cholera | 11 |
severe disease | 11 |
cxcr pd | 11 |
tumor virus | 11 |
patients presented | 11 |
duke university | 11 |
research institute | 11 |
pleural cavity | 11 |
adenovirus type | 11 |
iron depletion | 11 |
intestinal epithelial | 11 |
current state | 11 |
human papillomaviruses | 11 |
coronavirus spike | 11 |
gene product | 11 |
canine coronavirus | 11 |
four different | 11 |
new insights | 11 |
response element | 11 |
mast cell | 11 |
negative feedback | 11 |
laboratory data | 11 |
hb deferral | 11 |
cell processor | 11 |
years ago | 11 |
receptor sequences | 11 |
recombination event | 11 |
patient education | 11 |
i administration | 11 |
sugar handshake | 11 |
coding sequence | 11 |
nuclear export | 11 |
extrinsic allergic | 11 |
inflammatory reaction | 11 |
disseminated intravascular | 11 |
bacterial pathogens | 11 |
binding affinity | 11 |
cytokine responses | 11 |
foreign body | 11 |
much less | 11 |
titer anti | 11 |
iv molecular | 11 |
multisystemic wasting | 11 |
within minutes | 11 |
risk management | 11 |
well tolerated | 11 |
cytokine chemokine | 11 |
case study | 11 |
jak stat | 11 |
orf ab | 11 |
mouse models | 11 |
first months | 11 |
multocida isolates | 11 |
cutaneous adr | 11 |
may explain | 11 |
automated alinity | 11 |
adverse effect | 11 |
bronchiolar epithelium | 11 |
different mechanisms | 11 |
healthy individuals | 11 |
pulmonary defense | 11 |
end products | 11 |
type cells | 11 |
split rate | 11 |
barr virus | 11 |
hospital discharge | 11 |
expression data | 11 |
wide variety | 11 |
nip rhd | 11 |
fasting blood | 11 |
new cases | 11 |
prepare photographs | 11 |
toxicologic sampling | 11 |
family members | 11 |
least days | 11 |
post thaw | 11 |
diffuse interstitial | 11 |
mucociliary clearance | 11 |
developmental stages | 11 |
intravascular macrophages | 11 |
like cells | 11 |
producing cells | 11 |
alveolar injury | 11 |
transfusion safety | 11 |
abdominal cavity | 11 |
wasting syndrome | 11 |
plasma replacement | 11 |
studies show | 11 |
additional studies | 11 |
antigen typing | 11 |
innate lymphoid | 11 |
liver failure | 11 |
antibody titers | 11 |
diabetes prevention | 11 |
suspected underlying | 11 |
weight gain | 11 |
like protein | 11 |
glycemic control | 11 |
vaccine strain | 11 |
pulmonary abscesses | 11 |
disease patients | 11 |
antigen presentation | 11 |
also seen | 11 |
will provide | 11 |
higher prevalence | 11 |
also induce | 11 |
giant cell | 11 |
platelet transfusions | 11 |
sequence alignment | 11 |
sample collection | 11 |
northern blot | 11 |
bronchial epithelium | 11 |
onset diabetes | 11 |
pathogenic mutations | 11 |
superior vena | 11 |
lower levels | 11 |
cutaneous drug | 11 |
helicobacter pylori | 11 |
deleterious effects | 11 |
cyclic di | 11 |
hiv negative | 11 |
western blotting | 11 |
downstream signaling | 10 |
possible causes | 10 |
emergency units | 10 |
promoter region | 10 |
positive sera | 10 |
induced sjs | 10 |
gene regulation | 10 |
alcoholic liver | 10 |
wbc count | 10 |
study demonstrated | 10 |
donor program | 10 |
bariatric surgery | 10 |
i activity | 10 |
lymphoid hyperplasia | 10 |
generation sequencing | 10 |
rbc alloantibodies | 10 |
patients requiring | 10 |
titer results | 10 |
ii hyperplastic | 10 |
high resolution | 10 |
smoke inhalation | 10 |
year follow | 10 |
fresenius kabi | 10 |
underlying disease | 10 |
positive antibody | 10 |
high rate | 10 |
kupffer cells | 10 |
biliary atresia | 10 |
cross blood | 10 |
veterinary medicine | 10 |
main workbench | 10 |
platelet additive | 10 |
simulated patient | 10 |
blood banking | 10 |
human breast | 10 |
surfactant proteins | 10 |
expression profiles | 10 |
disease complex | 10 |
rna sequencing | 10 |
map kinase | 10 |
tract infection | 10 |
stored rbc | 10 |
spectra optia | 10 |
food poisoning | 10 |
recognition receptors | 10 |
stimulated gene | 10 |
ii positive | 10 |
medicine lists | 10 |
immune pathology | 10 |
control poults | 10 |
nuclear extracts | 10 |
mesangial cells | 10 |
fap primers | 10 |
nar library | 10 |
immunohematology reference | 10 |
alveolar edema | 10 |
diabetes among | 10 |
united kingdom | 10 |
may provide | 10 |
university medical | 10 |
discovery candidates | 10 |
accession numbers | 10 |
soft tissue | 10 |
infected animals | 10 |
consensus sequence | 10 |
western blot | 10 |
van gieson | 10 |
intestinal tract | 10 |
undiagnosed diabetes | 10 |
pulmonary tissue | 10 |
product wastage | 10 |
measured using | 10 |
cells may | 10 |
without fip | 10 |
rbc storage | 10 |
polyarteritis nodosa | 10 |
multidisciplinary approach | 10 |
kinase domain | 10 |
pcr products | 10 |
also contribute | 10 |
record volume | 10 |
samples showed | 10 |
olfactory sensory | 10 |
single donor | 10 |
inappropriate medications | 10 |
polymedicated patients | 10 |
intravascular coagulation | 10 |
formulary drugs | 10 |
ap donors | 10 |
insulin signaling | 10 |
significant improvement | 10 |
donor unit | 10 |
cell response | 10 |
granulomatous disease | 10 |
pulmonary infection | 10 |
done using | 10 |
mainly due | 10 |
endogenous retroviruses | 10 |
rhd xt | 10 |
zkv testing | 10 |
result verification | 10 |
id rhd | 10 |
might also | 10 |
interstitial lung | 10 |
ranked list | 10 |
immune signaling | 10 |
regression models | 10 |
mitochondrial dna | 10 |
analysis using | 10 |
bronchial mucosa | 10 |
crossmatch compatible | 10 |
negative bacteria | 10 |
identified using | 10 |
tissue factor | 10 |
online survey | 10 |
visceral pleura | 10 |
organic matter | 10 |
increased mortality | 10 |
umbilical cord | 10 |
intrinsic anti | 10 |
autoimmune hemolytic | 10 |
pulmonary injury | 10 |
fatty changes | 10 |
bronchiolitis obliterans | 10 |
may contain | 10 |
secretory cells | 10 |
infection may | 10 |
total counts | 10 |
cells within | 10 |
retropharyngeal lymph | 10 |
see syndrome | 10 |
total blood | 10 |
fluorescent antibody | 10 |
vein thrombosis | 10 |
stat signaling | 10 |
cgas sting | 10 |
viral clearance | 10 |
rbc alloimmunization | 10 |
squamous metaplasia | 10 |
groundwater recharge | 10 |
effector cells | 10 |
hydrops fetalis | 10 |
ttp patients | 10 |
cell tumor | 10 |
away time | 10 |
disease control | 10 |
antibody production | 10 |
great vessels | 10 |
arterial hypertension | 10 |
major types | 10 |
i receptor | 10 |
diagnostic criteria | 10 |
peg iat | 10 |
medical students | 10 |
operating room | 10 |
ifnb production | 10 |
packed red | 10 |
humoral immune | 10 |
antibiotic therapy | 10 |
pulmonary inflammation | 10 |
us blood | 10 |
equine viral | 10 |
weeks later | 10 |
interferon therapy | 10 |
chronically transfused | 10 |
htlv i | 10 |
dna polymerase | 10 |
autoimmune disease | 10 |
abo bw | 10 |
two weeks | 10 |
seq data | 10 |
rarely seen | 10 |
subsequent follow | 10 |
several days | 10 |
must also | 10 |
high viral | 10 |
medicine background | 10 |
blood sample | 10 |
hela cells | 10 |
cell growth | 10 |
primer pairs | 10 |
alveolar fibrosis | 10 |
patients will | 10 |
health services | 10 |
animal species | 10 |
right ventricular | 10 |
serum creatinine | 10 |
lymph vessels | 10 |
interstitial fibrosis | 10 |
nasal epithelium | 10 |
significant role | 10 |
ifn responses | 10 |
mammary tumor | 10 |
tissue samples | 10 |
mucous membranes | 10 |
exclusive types | 10 |
usually present | 10 |
post collection | 10 |
takes place | 10 |
apoptosis induction | 10 |
stop codon | 10 |
secondary prevention | 10 |
storage period | 10 |
domain antibody | 10 |
study highlights | 10 |
serologic weak | 10 |
maximum likelihood | 10 |
cell recruitment | 10 |
frequently used | 10 |
tnf receptor | 10 |
prepare histologic | 10 |
allelic loss | 10 |
tissue sections | 10 |
well known | 10 |
intermediate hosts | 10 |
feline calicivirus | 10 |
new process | 10 |
platelet activation | 10 |
interstitial emphysema | 10 |
affected lungs | 10 |
variable genes | 10 |
produce ifn | 10 |
baby units | 10 |
cell atlas | 10 |
years using | 10 |
testing using | 10 |
human coronaviruses | 10 |
diarrhea virus | 10 |
remained constant | 10 |
group vii | 10 |
five days | 10 |
severe dka | 10 |
lung lobes | 10 |
sensor cgas | 10 |
bar lm | 10 |
clc main | 10 |
slightly lower | 10 |
normal lungs | 10 |
tertiary hospital | 10 |
patient identification | 10 |
drug use | 10 |
following infection | 10 |
diverse range | 10 |
immune defenses | 10 |
platelet recovery | 10 |
prescription analysis | 10 |
iii interferon | 10 |
cell survival | 10 |
apheresis procedures | 10 |
embolic pneumonia | 10 |
health promotion | 10 |
vector control | 10 |
detection system | 10 |
may appear | 10 |
uninfected cells | 10 |
pulmonary pathology | 10 |
acute phase | 10 |
rbc antigens | 9 |
studies indicate | 9 |
ombitasvir paritaprevir | 9 |
took place | 9 |
phase red | 9 |
respiratory epithelium | 9 |
clinical diagnostics | 9 |
mucociliary escalator | 9 |
pharmacist interventions | 9 |
recently shown | 9 |
multinucleated giant | 9 |
three main | 9 |
groups given | 9 |
respiratory diseases | 9 |
pulmonary arterial | 9 |
pulmonary neoplasms | 9 |
without compromising | 9 |
od values | 9 |
drug events | 9 |
pg ml | 9 |
sciatic nerve | 9 |
dna virus | 9 |
blood order | 9 |
two samples | 9 |
days prior | 9 |
bone resorption | 9 |
submit tissue | 9 |
blood specimens | 9 |
low level | 9 |
hpv infection | 9 |
laboratory information | 9 |
mycophenolate mofetil | 9 |
cell antigen | 9 |
club cells | 9 |
des typ | 9 |
enteric coronavirus | 9 |
confidence interval | 9 |
basal cells | 9 |
recent advances | 9 |
endocrine cell | 9 |
janus kinase | 9 |
positive dat | 9 |
hpv detection | 9 |
skeletal roentgenograms | 9 |
kda protein | 9 |
limited data | 9 |
infected cats | 9 |
delayed hemolytic | 9 |
chlormethine gel | 9 |
gene transcription | 9 |
pulmonary vasculature | 9 |
postweaning multisystemic | 9 |
failed runs | 9 |
teg results | 9 |
reading frames | 9 |
indirect antiglobulin | 9 |
online appendices | 9 |
electron microscopic | 9 |
protein sequences | 9 |
cells expressed | 9 |
i response | 9 |
induced tgf | 9 |
genetic analysis | 9 |
ortho clinical | 9 |
type iv | 9 |
electronic health | 9 |
trima accel | 9 |
sensing pathway | 9 |
containing protein | 9 |
among blood | 9 |
lesions may | 9 |
data management | 9 |
three cases | 9 |
hospital setting | 9 |
one additional | 9 |
dengue virus | 9 |
nkt cells | 9 |
high volume | 9 |
end reads | 9 |
pulmonary stenosis | 9 |
functional properties | 9 |
conduction velocity | 9 |
surgical blood | 9 |
analysis reveals | 9 |
year retrospective | 9 |
factor viii | 9 |
platelet collections | 9 |
inflammatory disease | 9 |
tyrosine kinases | 9 |
hcv patients | 9 |
nasal flora | 9 |
permeability edema | 9 |
autopsy findings | 9 |
pancreatic islets | 9 |
chronic interstitial | 9 |
exact test | 9 |
mg every | 9 |
new york | 9 |
also identified | 9 |
storage conditions | 9 |
gut microbiota | 9 |
odds ratios | 9 |
human serum | 9 |
glucose control | 9 |
virus strain | 9 |
first line | 9 |
image analysis | 9 |
related discovery | 9 |
highly contagious | 9 |
subspecies holarctica | 9 |
receptor signaling | 9 |
teaching hospital | 9 |
previously published | 9 |
antigen receptor | 9 |
hla typing | 9 |
nasal septum | 9 |
secondary infection | 9 |
pleural adhesions | 9 |
offending drug | 9 |
type infection | 9 |
study included | 9 |
i induced | 9 |
information regarding | 9 |
cubic spline | 9 |
vesicular stomatitis | 9 |
see methods | 9 |
see section | 9 |
land treatment | 9 |
see ref | 9 |
host resistance | 9 |
igg antibodies | 9 |
org allotaxonometry | 9 |
activated protein | 9 |
pulmonary lobes | 9 |
african american | 9 |
ethylene glycol | 9 |
hcv genotype | 9 |
human blood | 9 |
laboratory results | 9 |
energy metabolism | 9 |
several weeks | 9 |
based analysis | 9 |
therapeutic effect | 9 |
pcr amplification | 9 |
surface receptors | 9 |
pulmonary vessels | 9 |
alveolar lumens | 9 |
virus inactivation | 9 |
standard operating | 9 |
cut surface | 9 |
using restricted | 9 |
gestational age | 9 |
related viruses | 9 |
inventory levels | 9 |
versus deleterious | 9 |
human endogenous | 9 |
caudal lobes | 9 |
tissue distribution | 9 |
routine quality | 9 |
i induction | 9 |
hospital system | 9 |
post transfusion | 9 |
transfusion practices | 9 |
table shows | 9 |
alcohol level | 9 |
phosphorylation sites | 9 |
type xii | 9 |
studied using | 9 |
aspergillus spp | 9 |
nuclear translocation | 9 |
data demonstrate | 9 |
clinic background | 9 |
shipping fever | 9 |
cell collection | 9 |
paritaprevir ritonavir | 9 |
cellular immune | 9 |
porphyria cutanea | 9 |
fusion protein | 9 |
bile acid | 9 |
domain antibodies | 9 |
time consuming | 9 |
tularensis subspecies | 9 |
patient interview | 9 |
inhibitory effect | 9 |
implementation period | 9 |
mature osns | 9 |
swine influenza | 9 |
pivotal role | 9 |
mg ml | 9 |
skin diseases | 9 |
aortic valve | 9 |
specific binding | 9 |
xenopus oocytes | 9 |
cd expression | 9 |
glucose level | 9 |
alcohol concentrations | 9 |
categorical variables | 9 |
special precautions | 9 |
dna samples | 9 |
human cd | 9 |
may induce | 9 |
rhce cehar | 9 |
cutanea tarda | 9 |
patients presenting | 9 |
endogenous retrovirus | 9 |
calf thymus | 9 |
cells via | 9 |
also examined | 9 |
organ samples | 9 |
evolutionary history | 9 |
functional polarization | 9 |
buffered saline | 9 |
cell maturation | 9 |
high concentrations | 9 |
chinese population | 9 |
septic transfusion | 9 |
also included | 9 |
receptor expression | 9 |
initiation factor | 9 |
offending agent | 9 |
choriomeningitis virus | 9 |
safe blood | 9 |
immucor neo | 9 |
i treatment | 9 |
streptococcus suis | 9 |
endothelial dysfunction | 9 |
label use | 9 |
endemic areas | 9 |
aplastic anemia | 9 |
stimulating factor | 9 |
well understood | 9 |
porcine epidemic | 9 |
chronic kidney | 9 |
one month | 9 |
failure modes | 9 |
congestive heart | 9 |
frequently seen | 9 |
cell antibodies | 9 |
xii collagen | 9 |
old woman | 9 |
cerus corporation | 9 |
kinase activity | 9 |
plasma wastage | 9 |
restricted cubic | 9 |
following parameters | 9 |
atypical carcinoids | 9 |
positive patients | 9 |
willebrand factor | 9 |
therapeutic options | 9 |
methods used | 9 |
related term | 9 |
many countries | 9 |
clone anti | 9 |
nat screening | 9 |
patient outcomes | 9 |
microbial infection | 9 |
liquid plasma | 9 |
neutralizing antibody | 9 |
porcine respiratory | 9 |
negative controls | 9 |
bovine pleuropneumonia | 9 |
ifn genes | 9 |
growth cones | 9 |
generated using | 9 |
combination therapy | 9 |
extracellular vesicles | 9 |
deleterious ifn | 9 |
nlrp inflammasome | 9 |
hla antibody | 9 |
rhd variant | 9 |
study demonstrates | 9 |
liver cirrhosis | 9 |
relatively high | 9 |
bone formation | 9 |
gas bubbles | 9 |
gene products | 9 |
basophil activation | 9 |
classical type | 9 |
national institute | 9 |
strongly expressed | 9 |
platelet adhesion | 9 |
antibody response | 9 |
bovine respiratory | 9 |
positive donations | 9 |
cytokine release | 9 |
day post | 9 |
human influenza | 9 |
heat shock | 9 |
i species | 9 |
pleural effusions | 9 |
intestinal epithelium | 9 |
receptor activation | 9 |
nadph oxidase | 9 |
findings indicate | 9 |
medication list | 9 |
vaccine strains | 9 |
lymphocytic choriomeningitis | 9 |
prepare skeletal | 9 |
epidemic diarrhea | 9 |
less often | 9 |
liver steatosis | 9 |
histophilus somni | 9 |
line treatment | 9 |
many patients | 9 |
porcine pleuropneumonia | 9 |
atrial septal | 9 |
laboratory studies | 9 |
different species | 9 |
postmortem examination | 9 |
regulon activity | 9 |
cigarette smoking | 9 |
cells kg | 9 |
atrial fibrillation | 9 |
study found | 9 |
petechial hemorrhages | 9 |
drug monitoring | 9 |
plasma volume | 9 |
drosophila melanogaster | 9 |
may include | 9 |
one system | 9 |
prepare sections | 9 |
time points | 9 |
volume processed | 9 |
cellular debris | 9 |
data sets | 9 |
rbc exchange | 9 |
molecular methods | 9 |
class ii | 9 |
platelet components | 9 |
general hospital | 9 |
medical examiner | 9 |
medical director | 9 |
allogeneic blood | 9 |
feline sera | 9 |
mouse brain | 9 |
lung inflammation | 9 |
pbs containing | 9 |
neoplastic cells | 9 |
von willebrand | 9 |
closed system | 9 |
like type | 9 |
prepare smears | 9 |
medication management | 9 |
epidemic keratoconjunctivitis | 9 |
stat stat | 8 |
associated molecular | 8 |
chapter respiratory | 8 |
core literature | 8 |
gammaretroviral env | 8 |
atlantic veterinary | 8 |
sendai virus | 8 |
record appearance | 8 |
hematological parameters | 8 |
gieson stain | 8 |
matched units | 8 |
also lead | 8 |
data set | 8 |
care providers | 8 |
paediatric population | 8 |
see part | 8 |
various types | 8 |
enterica serovar | 8 |
rh phenotype | 8 |
valproate concentrations | 8 |
cyclic dinucleotide | 8 |
muscular dystrophy | 8 |
total amount | 8 |
log reduction | 8 |
thrombin generation | 8 |
supplementary table | 8 |
real life | 8 |
platelet yield | 8 |
high molecular | 8 |
canine adenovirus | 8 |
hbc lineage | 8 |
often fatal | 8 |
two additional | 8 |
pathologic findings | 8 |
cell fate | 8 |
see poisoning | 8 |
developing countries | 8 |
specific primers | 8 |
i signatures | 8 |
immediate spin | 8 |
precursor lesions | 8 |
also causes | 8 |
manufacturing methods | 8 |
dependent collagen | 8 |
acute renal | 8 |
well established | 8 |
igm positive | 8 |
study will | 8 |
diabetic patient | 8 |
triglyceride levels | 8 |
second sample | 8 |
canine coronaviruses | 8 |
pseudomonas aeruginosa | 8 |
infected macrophages | 8 |
negative stain | 8 |
different levels | 8 |
early diagnosis | 8 |
expression level | 8 |
descriptive study | 8 |
alcohol intoxication | 8 |
may develop | 8 |
low titer | 8 |
lung tumors | 8 |
chronic pulmonary | 8 |
request verhoeff | 8 |
two viruses | 8 |
response elements | 8 |
acinar cells | 8 |
suppurative bronchopneumonias | 8 |
specific differences | 8 |
patent ductal | 8 |
two systems | 8 |
cells produce | 8 |
odds ratio | 8 |
automated gel | 8 |
cerebrospinal fluid | 8 |
gd pangolin | 8 |
collected data | 8 |
procedure cd | 8 |
laryngeal hemiplegia | 8 |
pcr assays | 8 |
adrenal glands | 8 |
cleavage site | 8 |
neck dissection | 8 |
underlying condition | 8 |
type query | 8 |
global protocol | 8 |
fibrinogen levels | 8 |
cprd aurum | 8 |
active role | 8 |
renal tubular | 8 |
proteins involved | 8 |
working group | 8 |
acute cases | 8 |
islet amyloid | 8 |
significantly greater | 8 |
virus strains | 8 |
false positives | 8 |
automated solid | 8 |
antiplatelet therapy | 8 |
control mice | 8 |
irradiated rbcs | 8 |
nephrotic syndrome | 8 |
viral entry | 8 |
treatment group | 8 |
rbc samples | 8 |
services background | 8 |
left ventricle | 8 |
bacterial toxins | 8 |
organizing pneumonia | 8 |
multiple endocrine | 8 |
elevated ifn | 8 |
secondary pulmonary | 8 |
killer cells | 8 |
time donors | 8 |
six patients | 8 |
new drugs | 8 |
often associated | 8 |
mice deficient | 8 |
health professional | 8 |
disease caused | 8 |
patients may | 8 |
emergent situations | 8 |
molecular biology | 8 |
cdna library | 8 |
matched platelets | 8 |
multocida strains | 8 |
directly related | 8 |
binding activity | 8 |
glass opacities | 8 |
data using | 8 |
central venous | 8 |
ferritin testing | 8 |
may act | 8 |
bacterial superinfection | 8 |
care pathway | 8 |
indirect immunofluorescence | 8 |
therapeutic range | 8 |
porcine reproductive | 8 |
reactive protein | 8 |
higher frequencies | 8 |
molecular patterns | 8 |
severe sepsis | 8 |
also assessed | 8 |
group ii | 8 |
will discuss | 8 |
hb levels | 8 |
ortho vision | 8 |
cytometric analysis | 8 |
granulation tissue | 8 |
supply chain | 8 |
bronchoalveolar lavage | 8 |
feedback loops | 8 |
scattered throughout | 8 |
medication information | 8 |
catalytic subunit | 8 |
antigenic variation | 8 |
wastage rates | 8 |
dna sequencing | 8 |
available data | 8 |
nurse sharks | 8 |
later stages | 8 |
virus retention | 8 |
coding region | 8 |
ascaris lumbricoides | 8 |
blood mononuclear | 8 |
first two | 8 |
mouse strains | 8 |
typing results | 8 |
also shown | 8 |
normal saline | 8 |
veterinary college | 8 |
platelet refractoriness | 8 |
expression profiling | 8 |
initial presentation | 8 |
neonatal diabetes | 8 |
leukemia virus | 8 |
improving patient | 8 |
texas initiative | 8 |
close contact | 8 |
mechanisms underlying | 8 |
solid organ | 8 |
cervical cancer | 8 |
common causes | 8 |
positive women | 8 |
simulated transfusion | 8 |
rna virus | 8 |
inflammatory processes | 8 |
one hour | 8 |
target cell | 8 |
deep sequencing | 8 |
bpn bottles | 8 |
give blood | 8 |
upload time | 8 |
treatment groups | 8 |
chordate prrp | 8 |
data show | 8 |
improve communication | 8 |
polypeptide specificity | 8 |
clart hpv | 8 |
laboratory testing | 8 |
perfuse one | 8 |
lineage tracing | 8 |
safety profile | 8 |
neck organs | 8 |
oneg patients | 8 |
host response | 8 |
viral antigens | 8 |
platelet aggregation | 8 |
breast cancers | 8 |
tested negative | 8 |
classification system | 8 |
per liter | 8 |
cobe spectra | 8 |
light chain | 8 |
binary channels | 8 |
routinely used | 8 |
study population | 8 |
healthcare services | 8 |
full length | 8 |
incident cases | 8 |
derived macrophages | 8 |
optic nerve | 8 |
product utilization | 8 |
iron supplementation | 8 |
human cell | 8 |
information available | 8 |
rh blood | 8 |
feline enteric | 8 |
institutional review | 8 |
high percentage | 8 |
turkey poults | 8 |
study evaluated | 8 |
subspecies tularensis | 8 |
confidence intervals | 8 |
culture media | 8 |
chest wall | 8 |
samples obtained | 8 |
viral rhinopneumonitis | 8 |
daily dose | 8 |
different blood | 8 |
protein tyrosine | 8 |
may serve | 8 |
multiple infections | 8 |
std fimbriae | 8 |